Amgen · 1 day ago
Senior Scientist - Targeted Protein Degradation
Thousand Oaks, CA
Full-time
Hybrid
Senior Level
$130K/yr - $152K/yr
5+ years expAmgen is a leading biotechnology company dedicated to serving patients living with serious illnesses. They are seeking a highly motivated Senior Scientist to support Molecular Glues discovery and establish phenotypic-based screening platforms, playing a central role in advancing Amgen’s strategy in emerging induced proximity technologies.
BiotechnologyHealth CareManufacturingPharmaceutical
Responsibilities
Design, establish, and implement phenotypic-based screening platforms to enable discovery of novel induced proximity mechanisms
Develop and optimize assays that capture cellular context, functional outcomes, and disease relevance
Work with automation and high-throughput screening teams to scale phenotypic platforms for broader application across IPP
Integrate advanced imaging, omics, and data science approaches to extract actionable biological insights from phenotypic screens
Apply diverse experimental approaches, including biochemical, biophysical, and cell biology techniques, to understand degrader mechanisms of action
Partner with cross-functional teams across IPP and external collaborators to broaden the scope of induced proximity drug discovery
Share insights through internal presentations, publications, and external conferences
Provide scientific mentorship to junior scientists and contribute to fostering an environment of curiosity and innovation
Qualification
Required
Doctorate degree PhD OR PharmD OR MD [and relevant post-doc where applicable]
Master's degree and 3 years of directly related experience
Bachelor's degree and 5 years of directly related experience
Preferred
PhD in Chemical Biology, Cell Biology, Biochemistry, Pharmacology, or related field, with postdoctoral training or equivalent industry experience
2+ years of relevant industry experience (biotechnology or pharmaceutical research)
Demonstrated expertise in targeted protein degradation, molecular glue biology, or proximity-based drug discovery
Hands-on experience developing and executing cellular assays or phenotypic screening approaches
Track record of assay development for high-content or high-throughput phenotypic screening, including use of automation and advanced imaging technologies
Proficiency in cellular and molecular biology techniques, such as CRISPR-based perturbations, proteomics, or transcriptomics applied to phenotypic readouts
Experience applying systems biology and data integration approaches to interpret complex phenotypic datasets
Strong scientific creativity with a record of publications, patents, or conference presentations in relevant fields
Excellent interpersonal and communication skills; ability to work collaboratively in a matrixed research environment
Benefits
A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions
Group medical, dental and vision coverage
Life and disability insurance
Flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models, including remote and hybrid work arrangements, where possible
Company
Amgen
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
10001+ employees
H1B Sponsorship
Amgen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (429)
2024 (485)
2023 (485)
2022 (540)
2021 (460)
2020 (444)
Funding
Current Stage
Public CompanyTotal Funding
$28.5B2022-12-12Post Ipo Debt· $28.5B
1983-06-17IPO
Leadership Team
Robert Bradway
Chairman and Chief Executive Officer
Jay Bradner
Executive Vice President of R&D, and Chief Scientific Officer
Recent News
The Motley Fool
2026-01-09
2026-01-09
BioWorld Financial Watch
2026-01-09
Company data provided by crunchbase